The National Institutes of Health Consensus Development Conference on Acoustic Neuroma brought together neurosurgeons, radiosurgeons, otologists, neurologists, audiologists, otolaryngologists, and other health care professionals as well as the public to reach agreement (1) on defining the clinical types of acoustic neuroma, (2) on which procedures are useful for screening and diagnosis, (3) on the options available for managing the disorder as well as the complications of treatment, and (4) on the key clinical and biological areas for future research. Following 2 days of presentations by experts and discussion by the audience, a consensus panel weighed the evidence and prepared their consensus statement. Among their findings, the panel concluded that (1) the term vestibular schwannoma is preferred over acoustic neuroma as these tumors are composed of Schwann cells and typically involve the vestibular rather than the acoustic division of the 8th cranial nerve; (2) treatment for vestibular schwannoma must be individualized and requires an experienced, well-integrated, multidisciplinary team approach; (3) surgery remains the treatment of choice, but research is needed on the relative benefits and risks of all management options, including pharmaceutical and other alternative medical treatments such as tumor suppressing agents; (4) routine intraoperative monitoring of the facial nerve should be included in surgical therapy for vestibular schwannoma; (5) neurofibromatosis 2 (NF2) should be carefully considered in all patients newly diagnosed with vestibular schwannoma, and, when found, genetic evaluation and counseling should be provided for all relevant family members; and (6) a registry for all patients with vestibular schwannoma, whether undergoing observation or active management, should be established.
美国国立卫生研究院关于听神经瘤的共识发展会议汇聚了神经外科医生、放射神经外科医生、耳科医生、神经科医生、听力学家、耳鼻喉科医生以及其他医疗保健专业人员和公众，以就以下方面达成共识：（1）定义听神经瘤的临床类型；（2）哪些程序对筛查和诊断有用；（3）治疗该疾病及其治疗并发症的可用选项；（4）未来研究的关键临床和生物学领域。在专家进行了两天的陈述和听众进行讨论之后，一个共识小组权衡了证据并准备了他们的共识声明。在他们的发现中，小组得出结论：（1）前庭神经鞘瘤这一术语比听神经瘤更可取，因为这些肿瘤由施万细胞组成，通常累及第8颅神经的前庭而非听觉分支；（2）前庭神经鞘瘤的治疗必须个体化，需要一个经验丰富、整合良好的多学科团队方法；（3）手术仍然是首选治疗方法，但需要对所有管理选项的相对益处和风险进行研究，包括药物治疗和其他替代医学治疗，如肿瘤抑制药物；（4）前庭神经鞘瘤的手术治疗应包括术中对面神经的常规监测；（5）所有新诊断为前庭神经鞘瘤的患者都应仔细考虑神经纤维瘤病2型（NF2），如果发现，应为所有相关家庭成员提供基因评估和咨询；（6）应为所有前庭神经鞘瘤患者建立登记册，无论他们是接受观察还是积极治疗。
